The global digital biomarkers market is set to witness a growth rate of 20% in the next 5 years. Rising prevalence of chronic diseases, growing adoption of wearables and smart devices, shift toward personalized and preventive healthcare, advancements in AI and machine learning, and pharmaceutical industry’s demand for efficient clinical trials, are some of the key factors driving the digital biomarkers market.
Digital biomarkers are objective, quantifiable physiological and behavioral data collected and measured through digital devices such as smartphones, wearables, and sensors. These biomarkers are used to monitor, predict, or diagnose health conditions in real time, providing continuous insights into a patient’s status outside traditional clinical settings. They are particularly useful in chronic disease management, mental health, and neurodegenerative disorders among others. Unlike traditional biomarkers that often require lab-based tests, digital biomarkers enable passive, non-invasive data collection. Advances in artificial intelligence and data analytics further enhance their utility, making them valuable tools for personalized medicine, remote monitoring, and efficient clinical trial design.
Download a free sample report now 👉
https://meditechinsights.com/digital-biomarkers-market/request-sample/
Growing adoption of wearables and smart devices to propel market demand
The growing adoption of wearables and smart devices is a major driver of the digital biomarkers market. Devices like smartwatches, fitness trackers, and mobile health apps enable continuous, real-time monitoring of physiological and behavioral data such as heart rate, sleep patterns, activity levels, and more. This constant data flow allows for early detection of health anomalies and supports proactive, personalized healthcare. As consumers become more health-conscious and comfortable with digital technologies, the widespread use of these devices fuels demand for digital biomarkers. Additionally, their integration with cloud platforms and AI analytics enhances clinical decision-making and supports remote patient monitoring.
Digital biomarkers powering the shift to decentralized clinical trials
The growth of remote and decentralized clinical trials is a key trend driving the digital biomarkers market. These trials leverage digital biomarkers to collect continuous, real-time patient data outside traditional clinical settings, reducing the need for in-person visits. This approach enhances patient recruitment, retention, and compliance while lowering operational costs. Wearables, mobile apps, and sensors enable seamless remote monitoring, making trials more inclusive and geographically flexible. As regulatory bodies increasingly recognize digital endpoints, the adoption of decentralized trial models is accelerating, positioning digital biomarkers as essential tools in transforming clinical research into a more patient-centric process.
Competitive Landscape Analysis
The global digital biomarkers market is marked by the presence of established and emerging market players such as BioSensics, ActiGraph, LLC; AliveCor, Inc.; Koneksa Health; Altoida; Amgen Inc.; Biogen; Empatica Inc.; IXICO plc; Neurotrack Technologies, Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Download a sample report for in-depth competitive insights
https://meditechinsights.com/digital-biomarkers-market/request-sample/
Global Digital Biomarkers Market Segmentation
This report by Medi-Tech Insights provides the size of the global digital biomarkers market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, therapeutic area, end user.
Market Size & Forecast (2023-2030), By Product, USD Million
• Wearable Devices
• Mobile Applications
• Sensors
• Software & Platforms
Market Size & Forecast (2023-2030), By Application, USD Million
• Disease Diagnosis
• Monitoring & Management
• Drug Development & Clinical Trials
• Predictive Risk Analysis
• Behavioural & Cognitive Assessment
• Others
Market Size & Forecast (2023-2030), By Therapeutic Area, USD Million
• Neurological Disorders
• Cardiovascular Diseases
• Diabetes & Metabolic Disorders
• Respiratory Diseases
• Psychiatric & Behavioural Health
• Sleep Disorders
• Others
Market Size & Forecast (2023-2030), By End User, USD Million
• Pharmaceutical & Biotech Companies
• Healthcare Providers
• Healthcare Payers
• Others
Market Size & Forecast (2023-2030), By Region, USD Million
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Rest of Asia Pacific
• Latin America
• Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
[email protected]
Top comments (0)